Drug Profile

CX 011

Alternative Names: CX-011

Latest Information Update: 28 May 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator CarthroniX
Class Antirheumatics; Small molecules
Mechanism of Action Cytokine receptor gp130 modulators; Interleukin 6 receptor modulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

No development reported Osteoarthritis

Most Recent Events

28 May 2024 No recent reports of development identified for preclinical development in Osteoarthritis in USA (Intra-articular, Injection)
14 Apr 2022 University of Southern California has a patent covering compositions and methods for modulating inflammatory and degenerative disorder
13 Apr 2022 CarthroniX plans to file an Investigational New Drug (IND) application with US FDA for Osteoarthritis in 2022

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com